ASGCT, Adcomm for Lilly’s Donanemab, Vertex Vs. Bluebird 5/8/2024
Generative AI Finds Its Footing in Drug Development 5/8/2024
BMS, J&J Losses Not the End of IRA Legal Battle 5/8/2024
Merck Snaps Up Small Startup in $208M Deal, Seeks to Improve Safety of ADCs 4/8/2024
BMS Sees Early ROI for $14B Karuna Buy with Phase III Schizophrenia Win 4/8/2024
ACC24 Roundup: Novo, Ionis Tout Cardio Victories and Boehringer, Lilly Disappoint 4/8/2024
5 Successful Phase III Oncology Trials in Q1 4/8/2024
The Next Wave of ADCs Could Treat Evasive Solid Tumors 4/8/2024
AstraZeneca, Daiichi Sankyo Win First Tumor-Agnostic HER2 FDA Approval for Enhertu 4/8/2024
FDA Again Rejects Supernus Drug-Device Combo for Parkinson’s Disease 4/8/2024
Opinion: The Next Generation of ADCs Will Improve Cancer Treatment 4/8/2024
GSK, Moderna and Pfizer are all looking at potential respiratory syncytial virus vaccine sales slumps thanks to recently updated CDC guidelines regarding the use of RSV shots in seniors.